Abbott

Corporate brand

Abbott is a global healthcare company spanning medical devices, diagnostics, nutrition and established pharmaceutical products.

Last updated October 14, 2026

Overview

Abbott is a multinational healthcare company headquartered in Illinois, United States. Its business traces back to Wallace Calvin Abbott's founding of the company in 1888. Originally built around medicines and medical preparations, Abbott has developed into a diversified healthcare group with four principal areas: diagnostics, medical devices, nutrition and established pharmaceuticals. Its diagnostics operations include laboratory diagnostics, rapid testing and molecular diagnostics. The medical-device portfolio includes diabetes care, cardiovascular products and cardiac rhythm management; the FreeStyle Libre continuous glucose monitoring system is one of the company's most recognizable product lines. Abbott's nutrition business serves infants, children, adults and people with specific nutritional needs, with brands such as Ensure and Similac holding significant recognition in various markets. Its pharmaceuticals business focuses on established medicines and selected therapeutic areas. Abbott serves hospitals, laboratories, healthcare professionals and consumers through global research, manufacturing and distribution activities. The brand combines clinical technology with everyday health management, although its exact product mix and market emphasis vary by country.

History

Abbott's history began in 1888, when Wallace Calvin Abbott established the business in Chicago, United States. The company initially focused on producing and selling medicinal preparations. As modern medicine, pharmaceuticals and clinical diagnostics developed, Abbott broadened its portfolio and evolved from a conventional drug maker into a diversified healthcare company. During the twentieth century, Abbott expanded into diagnostics, nutrition and medical devices through research, business development and acquisitions. Diagnostics enabled the company to serve hospitals and laboratories, while nutrition brought its brands into households and consumer markets. Medical devices extended the company into specialist areas including cardiovascular care, cardiac rhythm management and diabetes management. This diversification became a defining feature of the Abbott brand. In the twenty-first century, Abbott has continued to emphasize diagnostics, medical devices, nutrition and established pharmaceuticals. The company developed the FreeStyle Libre continuous glucose monitoring system in diabetes care, while Ensure and Similac became important nutrition brands in different markets. In 2013, Abbott separated its research-based pharmaceutical business into AbbVie, allowing Abbott to focus more clearly on diversified healthcare operations. It has since continued to invest in products and businesses across diagnostics, devices and nutrition.

2024
Abbott marks ten years of FreeStyle Libre
[6]FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
Abbott highlighted the tenth anniversary of the FreeStyle Libre platform and its expansion into newer generations and related glucose technologies.
2022
Sturgis infant-formula recall
[8]FDA Investigation of Cronobacter Infections: Powdered Infant Formulafda.gov
Abbott recalled selected powdered infant formulas made at its Sturgis, Michigan, facility after an FDA investigation involving Cronobacter sakazakii.
2020
Robert B. Ford becomes chief executive officer
[3]Robert B. Ford biographyabbott.com
Robert B. Ford succeeded Miles D. White as Abbott's president and chief executive officer.
2017
St. Jude Medical and Alere transactions completed
[12]St. Jude Medical and Alere transactions completedabbott.com
The transactions materially expanded Abbott's cardiovascular, neuromodulation, point-of-care and rapid-diagnostics portfolios.
2016
St. Jude Medical acquisition announced
[11]St. Jude Medical acquisition announcedabbott.com
Abbott announced a major transaction intended to expand its cardiovascular and neuromodulation businesses.
2014
FreeStyle Libre debuts in Europe
[6]FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
Abbott launched the first FreeStyle Libre system in Europe after redesigning its approach to continuous glucose monitoring.
2010
Solvay Pharmaceuticals acquired
[10]Abbott Laboratoriesen.wikipedia.org
The transaction expanded Abbott's established-pharmaceuticals business and international reach.
2009
Evalve acquired
[7]The MitraClip Storyabbott.com
Abbott acquired Evalve, the company associated with MitraClip transcatheter mitral-valve repair technology.
2004
TheraSense acquired
[10]Abbott Laboratoriesen.wikipedia.org
The acquisition strengthened Abbott's diabetes-care activities and contributed to the later development of FreeStyle Libre.
2001
Knoll pharmaceutical business acquired
[10]Abbott Laboratoriesen.wikipedia.org
Abbott acquired Knoll, expanding its pharmaceutical products and research capabilities.

Showing the 10 most recent.

Products and positioning

Science-led, diversified healthcare provider combining medical technology, diagnostics, nutrition and established medicines, with a strong emphasis on chronic-disease management, cardiovascular care, infant and adult nutrition, decentralized testing and consumer health data.

Diabetes technology · 2014
FreeStyle Libre
FreeStyle Libre is Abbott's family of wearable glucose-monitoring systems. A small sensor measures glucose in interstitial fluid and transmits readings to a reader or compatible smartphone application. The platform was designed to reduce the burden of conventional finger-stick testing and to make glucose trends more visible to people with diabetes and their healthcare professionals. Successive generations have emphasized smaller sensors, longer wear periods, improved accuracy, connectivity and broader access. Abbott has also extended the technology toward consumer wellness through Lingo.
Adult nutrition
Ensure
Ensure is Abbott's adult nutrition brand, offering shakes and related products intended to provide calories, protein, vitamins and minerals. Product formulations vary by market and may target general nutritional supplementation, weight maintenance, higher protein needs or specific nutritional situations. Ensure is sold through retail, pharmacy and healthcare channels and is one of Abbott Nutrition's best-known global consumer brands.
Infant nutrition
Similac
Similac is Abbott's principal infant-formula brand in the United States and several international markets. Its portfolio includes standard infant formulas and specialized products designed for selected feeding, digestive or nutritional needs. The brand has been central to Abbott Nutrition's business for decades, while also being associated with the 2022 recall of selected powdered products manufactured at the Sturgis, Michigan, facility.
Hydration and electrolyte products
Pedialyte
Pedialyte provides oral rehydration and electrolyte products, including ready-to-drink liquids, powders and frozen formats in selected markets. The brand is widely associated with hydration support for children and adults during fluid loss. Abbott markets Pedialyte through consumer, pharmacy and healthcare channels.
Diabetes nutrition
Glucerna
Glucerna is Abbott's nutrition brand for people managing diabetes or blood-glucose concerns. Products generally emphasize controlled carbohydrate profiles, protein and nutrition designed for use alongside an individual's broader dietary and medical plan. The portfolio includes shakes, powders and other formats that vary by country.
Laboratory diagnostics
Alinity
Alinity is a family of laboratory diagnostic systems and assays used in areas such as clinical chemistry, immunoassay, hematology, blood screening and molecular diagnostics. The platform is intended to help laboratories consolidate workflows, automate testing and process high volumes of patient samples. Products and regulatory clearances differ by market.
Laboratory diagnostics
ARCHITECT
ARCHITECT is Abbott's established laboratory-instrument and assay platform. It has been used for automated immunoassay and clinical chemistry testing in hospitals, reference laboratories and other diagnostic settings. ARCHITECT remains part of Abbott's broader laboratory-diagnostics portfolio alongside newer Alinity systems.
Point-of-care diagnostics
i-STAT
i-STAT is a point-of-care testing system designed to produce near-patient blood-test results using handheld analyzers and disposable cartridges. It is used in settings such as emergency care, critical care, operating rooms, ambulances and clinics where rapid results can support immediate clinical decisions.
Rapid diagnostics
BinaxNOW
BinaxNOW is Abbott's rapid-test brand, best known for lateral-flow and antigen tests used for infectious-disease screening and diagnosis. The product family gained major visibility during the COVID-19 pandemic, when Abbott supplied rapid SARS-CoV-2 tests for professional and, in some markets, consumer use.
Structural-heart device · 2008
MitraClip
MitraClip is a catheter-based transcatheter edge-to-edge repair system for selected patients with mitral regurgitation. The device uses a clip delivered through a catheter to approximate portions of the mitral valve and reduce leakage without conventional open-heart surgery. Abbott acquired Evalve, the company that developed the technology, in 2009 and has continued to update the platform.
Structural-heart device · 2020
TriClip
TriClip is Abbott's transcatheter edge-to-edge repair system for selected patients with tricuspid regurgitation. It adapts principles developed for MitraClip to the tricuspid valve. Abbott launched versions of TriClip in European and Canadian markets before receiving United States regulatory clearance for the TriClip G4 system.
Cardiac rhythm management
Aveir
Aveir is Abbott's leadless pacemaker platform. Unlike conventional pacemakers that use a subcutaneous generator connected to transvenous leads, leadless systems are implanted within the heart. Aveir products are intended for selected patients requiring pacing, with indications, configurations and availability varying by regulatory market.
Consumer glucose biosensor · 2024
Lingo
Lingo is Abbott's consumer-oriented glucose biosensor platform. It uses wearable glucose-sensing technology and a digital application to provide information about glucose patterns and lifestyle responses. Abbott positioned Lingo as a product for people interested in health and wellness insights rather than solely as a prescription diabetes-management device.

Controversies

2022
Sturgis infant-formula contamination investigation and recall
The FDA investigated complaints involving infants who consumed powdered formula produced at Abbott Nutrition's Sturgis, Michigan, plant. FDA investigators reported Cronobacter sakazakii in environmental samples, adverse inspection observations and company records concerning environmental contamination and product destruction. Abbott voluntarily recalled selected Similac, Alimentum and EleCare powdered formulas. The plant shutdown contributed to a severe United States infant-formula shortage and generated congressional, legal and regulatory scrutiny.
Source
2022
Infant-formula supply shortage and government scrutiny
Because Abbott was one of the largest United States infant-formula suppliers, the Sturgis recall and production suspension had effects beyond the recalled products. The episode intensified scrutiny of industry concentration, WIC supply arrangements, production resilience, regulatory oversight and the company's crisis communications.
Source

2022Abbott World Marathon Majors and Libre performance partnership
Global
Abbott has used its sponsorship of the Abbott World Marathon Majors and the FreeStyle Libre brand to connect glucose data, endurance performance and athlete education. The company highlighted the use of Libre Sense technology by elite athletes, including marathon runner Eliud Kipchoge.
Outcome. The campaign strengthened the association between Abbott, connected health data, endurance sport and consumer-facing diabetes technology.
Source
2020COVID-19 testing access campaign
United States · Global
During the COVID-19 pandemic, Abbott promoted rapid, molecular and laboratory testing products as tools for expanding testing access and supporting public-health responses.
Outcome. The BinaxNOW and related testing franchises became highly visible in public-health, workplace, school and travel-testing programs.
Source
2020Diversity and inclusion employer campaign
Global
Abbott used its corporate communications and workplace programs to promote diversity, inclusion and representation across its workforce and international operations.
Outcome. Abbott reported recognition from DiversityInc and continued to present workplace diversity as part of its corporate identity and operating model.
Source

Brand decisions

2024
Expand consumer and structural-heart platformsProduct launch
Background
Abbott continued to seek growth in connected health, consumer metabolic monitoring and minimally invasive cardiovascular procedures.
Action taken
Abbott highlighted FDA clearance for Lingo and approval for the TriClip G4 system among its major 2024 product and regulatory developments.
Aftermath
The decisions broadened Abbott's reach beyond traditional prescription care into wellness monitoring and expanded structural-heart treatment options.
Source
2022
Recall selected powdered infant formulasOther
Background
FDA investigation of Abbott's Sturgis facility identified environmental Cronobacter findings and reviewed reports of infant illness involving products made at the plant.
Action taken
Abbott voluntarily recalled selected Similac, Alimentum and EleCare powdered formulas and suspended production at the facility while corrective actions and regulatory reviews proceeded.
Aftermath
The recall contributed to a United States infant-formula shortage and generated significant regulatory, legal, political and reputational consequences.
Source
2020
Scale rapid COVID-19 testingStrategy
Background
The COVID-19 pandemic created urgent demand for rapid, molecular and laboratory diagnostic tests.
Action taken
Abbott expanded production, regulatory submissions and distribution of COVID-19 testing technologies, including BinaxNOW and laboratory platforms.
Aftermath
Abbott became one of the most visible suppliers of rapid COVID-19 tests, while the business also faced changing demand and regulatory requirements as the pandemic evolved.
Source
2017
Complete acquisition of AlereM&A
Background
Abbott sought to strengthen its point-of-care and rapid-diagnostics business and complement its laboratory-diagnostics operations.
Action taken
Abbott completed the acquisition of Alere and integrated its point-of-care diagnostics capabilities into Abbott's broader diagnostics organization.
Aftermath
The combination expanded Abbott's portfolio of rapid tests and helped support later infectious-disease testing programs.
Source
2016
Announce acquisition of St. Jude MedicalM&A
Background
Abbott pursued a larger position in cardiovascular devices, electrophysiology, cardiac rhythm management, heart failure and neuromodulation.
Action taken
Abbott announced an agreement to acquire St. Jude Medical, with the transaction completed in 2017.
Aftermath
The transaction created a broader medical-device platform and materially increased Abbott's presence in cardiovascular and neuromodulation markets.
Source
2014
Launch FreeStyle Libre in EuropeProduct launch
Background
Abbott's earlier FreeStyle Navigator continuous glucose monitor did not achieve the desired market impact, encouraging a redesign centered on usability, accessibility and affordability.
Action taken
Abbott launched the first FreeStyle Libre system in Europe, using a wearable sensor and digitally displayed glucose readings.
Aftermath
FreeStyle Libre developed into Abbott's leading diabetes-care franchise and a major connected-health platform.
Source
2009
Acquire Evalve to obtain MitraClip technologyM&A
Background
Abbott sought to expand its structural-heart portfolio through less-invasive treatments for mitral-valve disease.
Action taken
Abbott acquired Evalve, the company that developed the MitraClip transcatheter mitral-valve-repair system.
Aftermath
MitraClip became a major Abbott structural-heart franchise and served as a technological foundation for later tricuspid-valve repair products.
Source

Recent events

2025
Abbott reports full-year 2024 sales of approximately $42 billion[9]Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
Other
Abbott's published full-year 2024 results reported approximately $42 billion in worldwide sales and highlighted growth opportunities across medical devices, diagnostics, nutrition and established pharmaceuticals.
2024
FreeStyle Libre reaches its tenth anniversary[6]FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
Product generation · Product launch
Abbott marked ten years since the European debut of FreeStyle Libre, highlighting the platform's expansion from a redesigned continuous glucose monitor into a major diabetes-care franchise.
2024
FDA clears Abbott's Lingo glucose biosensor[9]Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
Product launch · Regulation
Lingo was introduced as a continuous glucose monitoring system available without a prescription and aimed at people interested in health and wellness insights.
2024
Abbott receives FDA approval for TriClip G4[9]Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
Product launch · Regulation
TriClip G4 was presented as a transcatheter edge-to-edge repair system designed for tricuspid regurgitation.
2017
Abbott completes acquisition of St. Jude Medical[11]St. Jude Medical acquisition announcedabbott.com
M&A
The completed acquisition expanded Abbott's cardiovascular, electrophysiology, heart-failure, cardiac-rhythm-management and neuromodulation businesses.
2017
Abbott completes acquisition of Alere[17]Abbott completes acquisition of Alereabbott.com
M&A
The transaction strengthened Abbott's point-of-care diagnostics and rapid-testing portfolio.

Sources18 sources

Cite this profile: Cite the canonical profile. /brand-wiki/abbott · Editorial policy · How profiles are compiled

Overview

History

2024
Abbott marks ten years of FreeStyle Libre
[6]FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
Abbott highlighted the tenth anniversary of the FreeStyle Libre platform and its expansion into newer generations and related glucose technologies.
2022
Sturgis infant-formula recall
[8]FDA Investigation of Cronobacter Infections: Powdered Infant Formulafda.gov
Abbott recalled selected powdered infant formulas made at its Sturgis, Michigan, facility after an FDA investigation involving Cronobacter sakazakii.
2020
Robert B. Ford becomes chief executive officer
[3]Robert B. Ford biographyabbott.com
Robert B. Ford succeeded Miles D. White as Abbott's president and chief executive officer.
2017
St. Jude Medical and Alere transactions completed
[12]St. Jude Medical and Alere transactions completedabbott.com
The transactions materially expanded Abbott's cardiovascular, neuromodulation, point-of-care and rapid-diagnostics portfolios.
2016
St. Jude Medical acquisition announced
[11]St. Jude Medical acquisition announcedabbott.com
Abbott announced a major transaction intended to expand its cardiovascular and neuromodulation businesses.
2014
FreeStyle Libre debuts in Europe
[6]FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
Abbott launched the first FreeStyle Libre system in Europe after redesigning its approach to continuous glucose monitoring.
2010
Solvay Pharmaceuticals acquired
[10]Abbott Laboratoriesen.wikipedia.org
The transaction expanded Abbott's established-pharmaceuticals business and international reach.
2009
Evalve acquired
[7]The MitraClip Storyabbott.com
Abbott acquired Evalve, the company associated with MitraClip transcatheter mitral-valve repair technology.
2004
TheraSense acquired
[10]Abbott Laboratoriesen.wikipedia.org
The acquisition strengthened Abbott's diabetes-care activities and contributed to the later development of FreeStyle Libre.
2001
Knoll pharmaceutical business acquired
[10]Abbott Laboratoriesen.wikipedia.org
Abbott acquired Knoll, expanding its pharmaceutical products and research capabilities.

Showing the 10 most recent.

Products and positioning

Diabetes technology · 2014
FreeStyle Libre
FreeStyle Libre is Abbott's family of wearable glucose-monitoring systems. A small sensor measures glucose in interstitial fluid and transmits readings to a reader or compatible smartphone application. The platform was designed to reduce the burden of conventional finger-stick testing and to make glucose trends more visible to people with diabetes and their healthcare professionals. Successive generations have emphasized smaller sensors, longer wear periods, improved accuracy, connectivity and broader access. Abbott has also extended the technology toward consumer wellness through Lingo.
Adult nutrition
Ensure
Ensure is Abbott's adult nutrition brand, offering shakes and related products intended to provide calories, protein, vitamins and minerals. Product formulations vary by market and may target general nutritional supplementation, weight maintenance, higher protein needs or specific nutritional situations. Ensure is sold through retail, pharmacy and healthcare channels and is one of Abbott Nutrition's best-known global consumer brands.
Infant nutrition
Similac
Similac is Abbott's principal infant-formula brand in the United States and several international markets. Its portfolio includes standard infant formulas and specialized products designed for selected feeding, digestive or nutritional needs. The brand has been central to Abbott Nutrition's business for decades, while also being associated with the 2022 recall of selected powdered products manufactured at the Sturgis, Michigan, facility.
Hydration and electrolyte products
Pedialyte
Pedialyte provides oral rehydration and electrolyte products, including ready-to-drink liquids, powders and frozen formats in selected markets. The brand is widely associated with hydration support for children and adults during fluid loss. Abbott markets Pedialyte through consumer, pharmacy and healthcare channels.
Diabetes nutrition
Glucerna
Glucerna is Abbott's nutrition brand for people managing diabetes or blood-glucose concerns. Products generally emphasize controlled carbohydrate profiles, protein and nutrition designed for use alongside an individual's broader dietary and medical plan. The portfolio includes shakes, powders and other formats that vary by country.
Laboratory diagnostics
Alinity
Alinity is a family of laboratory diagnostic systems and assays used in areas such as clinical chemistry, immunoassay, hematology, blood screening and molecular diagnostics. The platform is intended to help laboratories consolidate workflows, automate testing and process high volumes of patient samples. Products and regulatory clearances differ by market.
Laboratory diagnostics
ARCHITECT
ARCHITECT is Abbott's established laboratory-instrument and assay platform. It has been used for automated immunoassay and clinical chemistry testing in hospitals, reference laboratories and other diagnostic settings. ARCHITECT remains part of Abbott's broader laboratory-diagnostics portfolio alongside newer Alinity systems.
Point-of-care diagnostics
i-STAT
i-STAT is a point-of-care testing system designed to produce near-patient blood-test results using handheld analyzers and disposable cartridges. It is used in settings such as emergency care, critical care, operating rooms, ambulances and clinics where rapid results can support immediate clinical decisions.
Rapid diagnostics
BinaxNOW
BinaxNOW is Abbott's rapid-test brand, best known for lateral-flow and antigen tests used for infectious-disease screening and diagnosis. The product family gained major visibility during the COVID-19 pandemic, when Abbott supplied rapid SARS-CoV-2 tests for professional and, in some markets, consumer use.
Structural-heart device · 2008
MitraClip
MitraClip is a catheter-based transcatheter edge-to-edge repair system for selected patients with mitral regurgitation. The device uses a clip delivered through a catheter to approximate portions of the mitral valve and reduce leakage without conventional open-heart surgery. Abbott acquired Evalve, the company that developed the technology, in 2009 and has continued to update the platform.
Structural-heart device · 2020
TriClip
TriClip is Abbott's transcatheter edge-to-edge repair system for selected patients with tricuspid regurgitation. It adapts principles developed for MitraClip to the tricuspid valve. Abbott launched versions of TriClip in European and Canadian markets before receiving United States regulatory clearance for the TriClip G4 system.
Cardiac rhythm management
Aveir
Aveir is Abbott's leadless pacemaker platform. Unlike conventional pacemakers that use a subcutaneous generator connected to transvenous leads, leadless systems are implanted within the heart. Aveir products are intended for selected patients requiring pacing, with indications, configurations and availability varying by regulatory market.
Consumer glucose biosensor · 2024
Lingo
Lingo is Abbott's consumer-oriented glucose biosensor platform. It uses wearable glucose-sensing technology and a digital application to provide information about glucose patterns and lifestyle responses. Abbott positioned Lingo as a product for people interested in health and wellness insights rather than solely as a prescription diabetes-management device.

Controversies

2022
Sturgis infant-formula contamination investigation and recall
The FDA investigated complaints involving infants who consumed powdered formula produced at Abbott Nutrition's Sturgis, Michigan, plant. FDA investigators reported Cronobacter sakazakii in environmental samples, adverse inspection observations and company records concerning environmental contamination and product destruction. Abbott voluntarily recalled selected Similac, Alimentum and EleCare powdered formulas. The plant shutdown contributed to a severe United States infant-formula shortage and generated congressional, legal and regulatory scrutiny.
Source
2022
Infant-formula supply shortage and government scrutiny
Because Abbott was one of the largest United States infant-formula suppliers, the Sturgis recall and production suspension had effects beyond the recalled products. The episode intensified scrutiny of industry concentration, WIC supply arrangements, production resilience, regulatory oversight and the company's crisis communications.
Source

Marketing campaigns

2022Abbott World Marathon Majors and Libre performance partnership
Global
Abbott has used its sponsorship of the Abbott World Marathon Majors and the FreeStyle Libre brand to connect glucose data, endurance performance and athlete education. The company highlighted the use of Libre Sense technology by elite athletes, including marathon runner Eliud Kipchoge.
Outcome. The campaign strengthened the association between Abbott, connected health data, endurance sport and consumer-facing diabetes technology.
Source
2020COVID-19 testing access campaign
United States · Global
During the COVID-19 pandemic, Abbott promoted rapid, molecular and laboratory testing products as tools for expanding testing access and supporting public-health responses.
Outcome. The BinaxNOW and related testing franchises became highly visible in public-health, workplace, school and travel-testing programs.
Source
2020Diversity and inclusion employer campaign
Global
Abbott used its corporate communications and workplace programs to promote diversity, inclusion and representation across its workforce and international operations.
Outcome. Abbott reported recognition from DiversityInc and continued to present workplace diversity as part of its corporate identity and operating model.
Source

Brand decisions

2024
Expand consumer and structural-heart platformsProduct launch
Background
Abbott continued to seek growth in connected health, consumer metabolic monitoring and minimally invasive cardiovascular procedures.
Action taken
Abbott highlighted FDA clearance for Lingo and approval for the TriClip G4 system among its major 2024 product and regulatory developments.
Aftermath
The decisions broadened Abbott's reach beyond traditional prescription care into wellness monitoring and expanded structural-heart treatment options.
Source
2022
Recall selected powdered infant formulasOther
Background
FDA investigation of Abbott's Sturgis facility identified environmental Cronobacter findings and reviewed reports of infant illness involving products made at the plant.
Action taken
Abbott voluntarily recalled selected Similac, Alimentum and EleCare powdered formulas and suspended production at the facility while corrective actions and regulatory reviews proceeded.
Aftermath
The recall contributed to a United States infant-formula shortage and generated significant regulatory, legal, political and reputational consequences.
Source
2020
Scale rapid COVID-19 testingStrategy
Background
The COVID-19 pandemic created urgent demand for rapid, molecular and laboratory diagnostic tests.
Action taken
Abbott expanded production, regulatory submissions and distribution of COVID-19 testing technologies, including BinaxNOW and laboratory platforms.
Aftermath
Abbott became one of the most visible suppliers of rapid COVID-19 tests, while the business also faced changing demand and regulatory requirements as the pandemic evolved.
Source
2017
Complete acquisition of AlereM&A
Background
Abbott sought to strengthen its point-of-care and rapid-diagnostics business and complement its laboratory-diagnostics operations.
Action taken
Abbott completed the acquisition of Alere and integrated its point-of-care diagnostics capabilities into Abbott's broader diagnostics organization.
Aftermath
The combination expanded Abbott's portfolio of rapid tests and helped support later infectious-disease testing programs.
Source
2016
Announce acquisition of St. Jude MedicalM&A
Background
Abbott pursued a larger position in cardiovascular devices, electrophysiology, cardiac rhythm management, heart failure and neuromodulation.
Action taken
Abbott announced an agreement to acquire St. Jude Medical, with the transaction completed in 2017.
Aftermath
The transaction created a broader medical-device platform and materially increased Abbott's presence in cardiovascular and neuromodulation markets.
Source
2014
Launch FreeStyle Libre in EuropeProduct launch
Background
Abbott's earlier FreeStyle Navigator continuous glucose monitor did not achieve the desired market impact, encouraging a redesign centered on usability, accessibility and affordability.
Action taken
Abbott launched the first FreeStyle Libre system in Europe, using a wearable sensor and digitally displayed glucose readings.
Aftermath
FreeStyle Libre developed into Abbott's leading diabetes-care franchise and a major connected-health platform.
Source
2009
Acquire Evalve to obtain MitraClip technologyM&A
Background
Abbott sought to expand its structural-heart portfolio through less-invasive treatments for mitral-valve disease.
Action taken
Abbott acquired Evalve, the company that developed the MitraClip transcatheter mitral-valve-repair system.
Aftermath
MitraClip became a major Abbott structural-heart franchise and served as a technological foundation for later tricuspid-valve repair products.
Source

Recent events

2025
Abbott reports full-year 2024 sales of approximately $42 billion[9]Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
Other
Abbott's published full-year 2024 results reported approximately $42 billion in worldwide sales and highlighted growth opportunities across medical devices, diagnostics, nutrition and established pharmaceuticals.
2024
FreeStyle Libre reaches its tenth anniversary[6]FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
Product generation · Product launch
Abbott marked ten years since the European debut of FreeStyle Libre, highlighting the platform's expansion from a redesigned continuous glucose monitor into a major diabetes-care franchise.
2024
FDA clears Abbott's Lingo glucose biosensor[9]Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
Product launch · Regulation
Lingo was introduced as a continuous glucose monitoring system available without a prescription and aimed at people interested in health and wellness insights.
2024
Abbott receives FDA approval for TriClip G4[9]Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
Product launch · Regulation
TriClip G4 was presented as a transcatheter edge-to-edge repair system designed for tricuspid regurgitation.
2017
Abbott completes acquisition of St. Jude Medical[11]St. Jude Medical acquisition announcedabbott.com
M&A
The completed acquisition expanded Abbott's cardiovascular, electrophysiology, heart-failure, cardiac-rhythm-management and neuromodulation businesses.
2017
Abbott completes acquisition of Alere[17]Abbott completes acquisition of Alereabbott.com
M&A
The transaction strengthened Abbott's point-of-care diagnostics and rapid-testing portfolio.

Overview

History

Products and positioning

Controversies

Marketing campaigns

Brand decisions

Recent events

Related entries

Sources18 sources

Overview

History

Products and positioning

Controversies

Marketing campaigns

Brand decisions

Recent events

Related entries

Sources18 sources